Antiproliferative effect of hepatitis C virus on mitogen-stimulated peripheral blood mononuclear cells: Potential role in viral persistence in Egyptian patients

Clinical Biochemistry

Volumn 40, Issue 16-17, 2007, Pages 1173-1179

  Hassan, Mahmoud I ^a   Kassim, Samar K ^a   Ahmad, Maha I ^a   Fawzy, Shereen ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

HCV; HCV bDNA; IL 4; IL1 ; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; RNA; THYMIDINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; EGYPT; ENZYME IMMUNOASSAY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CELL PROLIFERATION; EGYPT; HEPACIVIRUS; HEPATITIS C, CHRONIC; INTERLEUKIN-1BETA; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LIVER FUNCTION TESTS; MITOGENS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348861549     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.07.012     Document Type: Article

References (56)

1. Seeff L.B. Natural history of viral hepatitis, type C. Semin. Gastointest. Dis. 6 (1995) 20-27
2. Brown P.M.J., and Neuman M.G. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin. Biochem. 34 (2001) 167-171
3. Iwata K., Wakita T., Okumura A., et al. Interferon-γ production by peripheral blood lymphocytes to hepatitis C virus core protein in chronic hepatitis C infection. Hepatology 22 (1995) 1057-1064
4. Koziel M.J., Dudley D., Afdhal N., et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. J. Clin. Invest. 96 (1995) 2311-2321
5. Swans S., Weinberg A.D., English M., and Huston G. IL-4 directs the development of Th-like helper effectors. J. Immunol. 145 (1990) 3796-3806
6. Isaguliants M.G. Hepatitis C virus clearance: the enigma of failure despite an impeccable survival strategy. Curr. Pharm. Biotechnol. 4 (2003) 169-183
7. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194 (2001) 1395-1406
8. Chen M., Sallberg M., Sonnerborg A., Weiland O., Mattsson L., Jin L., et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 116 (1999) 135-143
9. Rentenaar R.J., Gamadia L.E., van Der Hoek N., et al. Development of virus-specific CD4 (+) T cells during primary cytomegalovirus infection. J. Clin. Invest. 105 (2000) 541-548
10. Isaguliants M.G., and Ozeretskovskaya N.N. Host background factors contributing to hepatitis C virus clearance. Curr. Pharm. Biotechnol. 4 (2003) 185-193
11. Kuo G., Choo Q.L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244 (1989) 362-364
12. Ravaggi A., Primi D., and Cariani E. Direct PCR amplification of HCV RNA from human serum. PCR Methods Appl. 1 (1992) 291-292
13. Kwok S., and Higushi R. Avoiding false positives with PCR. Nature 339 (1989) 237-238
14. Okamoto H., Okada S., Sugiyama Y., et al. The 5-terminal sequence of the hepatitis C genome. Jpn. J. Exp. Med. 60 (1990) 167-177
15. Okamoto H., Okada S., and Sugiyama Y. Detection of hepatitis C virus RNA by a two stage polymerase chain reaction with two pairs of primers deduced from the 5′ non coding region. Jpn. J. Exp. Med. 60 (1990) 215-222
16. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning. 3rd ed. vol. 18 (1989), Cold Spring Harbor Laboratory, Cold Spring Harbor 42-59
17. Detmer J., Lagier R., Flynn J., et al. Accurate quantification of hepatitis C virus (HCV RNA) from all HCV genotypes by using branched-DNA technology. J. Clin. Microbiol. 34 (1996) 901-907
18. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J.Clin. Invest. 97 (1968) 77-88
19. Snyder C.A., and Valle C.D. Lymphocytes proliferation assays as potential biomarkers for toxicant exposure. J. Toxicol. Environ. Health 34 (1991) 127-139
20. Nokta M.A., Hassan M.I., Loesch K.Y., and Pollard R.B. HIV-induced TNF-α regulates arachidonic acid and PGE2 release from HIV-infected mononuclear phagocytes. Virology 208 (1995) 590-600
21. Yamazaki S., Onishi E., Enami K., et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn. J. Med. Sci. Biol. 39 (1986) 105-118
22. Ruiz-Arguelles G.J. Laboratory measurement of human cytokines. JIFCC 7 (1995) 12-15
23. Henderson R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann. Clin. Biochem. 30 (1993) 521-539
24. Mizukoshi E., and Rehermann B. Immune responses and immunity in hepatitis C virus infection. J. Gastroenterol. 36 (2001) 799-808
25. Pavio N., and Lai M.M.C. The hepatitis C virus persistence: how to evade the immune system?. J. Biosci. 28 (2003) 287-304
26. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 (2002) 43-49
27. Fowler N.L., Torresi J., Jackson D.C., Brown L.E., and Gowans E.J. Immune responses in hepatitis C virus infection: the role of dendritic cells. Immunol. Cell Biol. 81 (2003) 63-66
28. Polyak S.J., Khabar K.S., Paschal D.M., et al. Hepatitis C virus nonstructural 5A protein induces interleukin- 8, leading to partial inhibition of the interferon induced antiviral response. J. Virol. 75 (2001) 6095-6106
29. Yao Z.Q., King E., Prayther D., Yin D., and Moorman J. T cell dysfunction by Hepatitis C core protein involves PD-1/PDL-1 signaling. Viral Immunol. 20 (2007) 276-287
30. Flint M., Haidens C., Loomis-Price L.D., et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73 (1999) 6235-6244
31. Bertoletti A., and Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 38 (2003) 4-13
32. Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut 44 (1999) 759-764
33. Moorman J.P., Joo M., and Hahn Y.S. Evasion of host immune surveillance by hepatitis C virus: potential roles in viral persistence. Arch. Immunol. Ther. Exp. (Warsz) 49 (2001) 189-194
34. Lechmann M., and Liang T.J. Vaccine development for hepatitis C. Semin. Liver Dis. 20 (2000) 211-226
35. Ray S.C., Wang Y.M., Laeyendecker O., Ticehurst J.R., Villano S.A., and Thomas D.L. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73 (1999) 2938-2946
36. Cabot B., Martell M., and Esteban J.I. Nucleotide and amino acid complexity of hepatitis C virus quasispecies in serum and liver. J. Virol. 74 (2000) 805-811
37. Toubi E., Kessel A., Goldstein L., et al. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J. Hepatol. 35 (2001) 774-780
38. Taya N., Torimoto Y., Shindo M., Hirai K., Hasebe C., and Kohgo Y. Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br. J. Haematol. 110 (2000) 89-97
39. Sabile A., Perlemuter G., Bono F., et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 30 (1999) 1064
40. Muratori L., and Gibellini D. A new route to apoptosis in hepatitis C virus infection. J. Hepatol. 35 (2001) 814-815
41. Hahn C.S., Cho Y.G., Kang B.S., Lester I.M., and Hahn Y.S. The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology 276 (2000) 127-137
42. Yao Z.Q., King E., Prayther D., Yin D., and Moorman J. T cell dysfunction by hepatitis C core protein involves PD-1/PDL-1 signaling. Viral Immunol. 20 (2007) 276-287
43. Zhu N.L., Khoshnan A., Schneider R., et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J. Virol. 72 (1998) 3691-3697
44. Liu Z.G., and Han J. Cellular responses to tumor necrosis factor. Curr. Issues Mol. Biol. 3 (2001) 79-90
45. Kountouras J., Zavos C., and Chatzopoulos D. Apoptosis in C. hepatitis. J. Viral Hepatitis. 10 (2003) 335-342
46. Larrea E., Garcia N., Qian C., Civeira M.P., and Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23 (1996) 210-217
47. Radkowski M., Bednarska A., Horban A., et al. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor- and interleukin 8. J. Gen. Virol. 85 (2004) 47-59
48. Frese M., Barth K., Kaul A., Lohmann V., Schwärzle V., and Bartenschlager R. Hepatitis C virus RNA replication is resistant to tumour necrosis factor. J. Gen. Virol. 84 (2003) 1253-1259
49. Müller C., Knoflach P., and Zielinski C.C. Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis. Dig. Dis. Sci. 38 (1993) 477-481
50. Dumoulin F.L., Leifeld L., Honecker U., Sauerbruch T., and Spengler U. Intrahepatic expression of interleukin-1β and tumor necrosis factor-α in chronic C. hepatitis. J. Infect. Dis. 180 (1999) 1704-1708
51. Libra M., Mangano K., Anzaldi M., et al. Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol. Rep. 15 (2006) 1305-1308
52. Fan X.G., Liu W.E., Li C.Z., et al. Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediat. Inflamm. 7 (1998) 295-297
53. Abayli B., Canataroǧlu A., and Akkiz H. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 14 (2003) 7-11
54. Sobchak D.M., Korochkina O.V., and Monakova E.A. Cytokine spectrum in patients with chronic hepatitis C in the treatment with interferon-alpha drugs. Ter. Arkh. 77 (2005) 70-72
55. Gattoni A., Parlato A., Vangieri B., Bresciani M., and Derna R. Interferon-gamma: biologic functions and HCV therapy (type I/II) (2 of 2 parts). Clin. Ter. 157 (2006) 457-468
56. Rehermann B. Interaction between the hepatitis C virus and the immune system. Semin. Liver Dis. 20 (2000) 127-141